Selank the science.

Selank is a synthetic heptapeptide derived from tuftsin, a naturally occurring immunomodulatory peptide, with additional amino acids added to improve stability. It was developed at Russian research institutes as an investigational anxiolytic and has been studied as a tool for probing neuropeptide modulation of mood- and anxiety-related behavior.

Unlike many compounds in this catalog, Selank has been the subject of some human studies in its country of origin, though it is not approved by the FDA and is supplied here strictly for research use.

Selank research has examined several connected mechanisms:

• GABAergic signaling — interactions with the GABA system, frequently invoked in anxiolytic research.
• BDNF & neuroplasticity — effects on brain-derived neurotrophic factor expression in animal models.
• Monoamine & immune modulation — influences on neurotransmitter balance and, reflecting its tuftsin origin, immune-related signaling.

Selank has been studied in animal models and some human studies, much of it from Russian research groups:

• Behavioral / withdrawal models (2022). A study in the Bulletin of Experimental Biology and Medicine reported that Selank, a peptide analog of tuftsin, attenuated aversive signs of morphine withdrawal in a rodent model.
• Anxiolytic mechanism research. Additional preclinical work has examined Selank’s effects on anxiety-related behavior, GABAergic signaling, and gene expression.

These are findings in animals plus limited human studies; broad human therapeutic use is not established outside its original research context.

The Selank evidence base combines animal models with some human studies, largely from Russian research. It is not FDA-approved, and no approved indication, dosing, or therapeutic claim applies in the United States. Selank is supplied strictly as a research material for laboratory investigation.